Headquartered in Teaneck, NJ Fiscal year ends June NASDAQ: PAHC pahc.com
Phibro Animal Health Corporation (Nasdaq: PAHC) is a global diversified animal health and mineral nutrition company. It serves livestock producers, farmers, veterinarians and consumers who raise or care for farm and companion animals. It operates three reporting segments:
- Animal Health is the largest segment. It covers medicated feed additives (MFAs) and other products, including virginiamycin and ethanol processing aids; nutritional specialty products for poultry, aquaculture and companion animals; and vaccines and adjuvant products for poultry and swine.
- Mineral Nutrition sells zinc oxide, copper and trace mineral products.
- Performance Products sells copper-based and fluoride products.
The company expanded its MFA portfolio through the acquisition of Zoetis' MFA portfolio, completed in October 2024. Its key markets include North America, Brazil and the broader South America region, and Asia, including China. It is currently pursuing regulatory approvals for therapeutic claims for virginiamycin in Brazil and plans to close its Chicago Heights, Illinois manufacturing facility. It also runs 'Phibro Forward' income growth initiatives. Updated
Guidance assumes zero virginiamycin sales in Brazil for the rest of fiscal 2027, so a pending regulatory approval there is free upside the $832 million market cap isn't paying for. The quarter itself cleared both lines, with Mineral Nutrition up 17% covering a $5.2 million Brazil hit.
One of Wall Street’s top firms just gave a thumbs-up to Zoetis (NYSE:ZTS | ZTS Price Prediction) stock. Citi initiated coverage with a Buy rating and a $145 price target, naming it…
Phibro Animal Health Corporation (Nasdaq: PAHC) is a global diversified animal health and mineral nutrition company. It serves livestock producers, farmers, veterinarians and consumers who raise or care for farm and companion animals.
The Wall Street consensus 12-month price target for PAHC is $47.00.
